KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) Gross Margin (2016 - 2026)

Pacific Biosciences Of California has reported Gross Margin over the past 16 years, most recently at 37.11% for Q4 2025.

  • For Q4 2025, Gross Margin rose 1146.0% year-over-year to 37.11%; the TTM value through Dec 2025 reached 28.61%, up 440.0%, while the annual FY2025 figure was 28.61%, 440.0% up from the prior year.
  • Gross Margin for Q4 2025 was 37.11% at Pacific Biosciences Of California, down from 41.36% in the prior quarter.
  • Over five years, Gross Margin peaked at 46.55% in Q4 2021 and troughed at 3.69% in Q1 2025.
  • A 5-year average of 31.55% and a median of 32.68% in 2023 define the central range for Gross Margin.
  • On a YoY basis, Gross Margin climbed as much as 2044bps in 2025 and fell as far as -3276bps in 2025.
  • Year by year, Gross Margin stood at 46.55% in 2021, then crashed by -60bps to 18.79% in 2022, then fell by -13bps to 16.4% in 2023, then soared by 56bps to 25.64% in 2024, then surged by 45bps to 37.11% in 2025.
  • Business Quant data shows Gross Margin for PACB at 37.11% in Q4 2025, 41.36% in Q3 2025, and 36.93% in Q2 2025.